BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20567018)

  • 1. Parent opinions regarding the genetic testing of minors for BRCA1/2.
    Bradbury AR; Patrick-Miller L; Egleston B; Sands CB; Li T; Schmidheiser H; Feigon M; Ibe CN; Hlubocky FJ; Hope K; Jackson S; Corbman M; Olopade OI; Daly M; Daugherty CK
    J Clin Oncol; 2010 Jul; 28(21):3498-505. PubMed ID: 20567018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.
    Bradbury AR; Patrick-Miller L; Pawlowski K; Ibe CN; Cummings SA; Olopade OI; Daugherty CK
    Am J Med Genet C Semin Med Genet; 2008 Feb; 148C(1):70-7. PubMed ID: 18200524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults.
    Bradbury AR; Dignam JJ; Ibe CN; Auh SL; Hlubocky FJ; Cummings SA; White M; Olopade OI; Daugherty CK
    J Clin Oncol; 2007 Aug; 25(24):3705-11. PubMed ID: 17704419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation.
    Hamann HA; Croyle RT; Venne VL; Baty BJ; Smith KR; Botkin JR
    Am J Med Genet; 2000 May; 92(1):25-32. PubMed ID: 10797419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phases of disclosing BRCA1/2 genetic information to offspring.
    Clarke S; Butler K; Esplen MJ
    Psychooncology; 2008 Aug; 17(8):797-803. PubMed ID: 18646247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell.
    Patenaude AF; Dorval M; DiGianni LS; Schneider KA; Chittenden A; Garber JE
    J Clin Oncol; 2006 Feb; 24(4):700-6. PubMed ID: 16446344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interest in BRCA1/2 testing in a primary care population.
    Armstrong K; Weber B; Ubel PA; Guerra C; Schwartz JS
    Prev Med; 2002 Jun; 34(6):590-5. PubMed ID: 12052018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort.
    Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J
    Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
    Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
    Wagner Costalas J; Itzen M; Malick J; Babb JS; Bove B; Godwin AK; Daly MB
    Am J Med Genet C Semin Med Genet; 2003 May; 119C(1):11-8. PubMed ID: 12704633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M; Gauthier G; Maunsell E; Dugas MJ; Rouleau I; Chiquette J; Plante M; Laframboise R; Gaudet M; Bridge PJ; Simard J
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic testing of minors for alpha1-antitrypsin deficiency.
    Strange C; Moseley MA; Jones Y; Schwarz L; Xie L; Brantly ML
    Arch Pediatr Adolesc Med; 2006 May; 160(5):531-4. PubMed ID: 16651497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
    Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.